International Leukemia Expert Hagop Kantarjian Joins ChemGenex Scientific Advisory Board
| BIOWIRE2K |
MELBOURNE, Australia, & MENLO PARK, Calif.--(BUSINESS WIRE)--Sept. 21, 2004--ChemGenex Pharmaceuticals (ASX:CXS) announced today that Hagop Kantarjian, M.D. has joined the company's Scientific Advisory Board (SAB). Dr. Kantarjian is chairman of the Leukemia Department and a professor of Medicine at the University of Texas, M.D. Anderson Cancer Center.
"Dr. Kantarjian is a leading expert in the field of chronic and acute leukemia and was a key investigator in clinical trials that led to the approval of Gleevec(R) as a treatment for chronic myeloid leukemia (CML)," said Dennis Brown PhD, ChemGenex Pharmaceuticals president. "He has also been instrumental in the development of our lead drug, Ceflatonin(R) (homoharringtonine), which is in Phase II studies for the treatment of CML. His further participation, as a member of the ChemGenex SAB, will serve our company well as we broaden investigations of this compound to myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and other forms of leukemia. We also look forward to his help in identifying promising new targeted agents to move into the clinic."
"ChemGenex's lead compound, homoharringtonine, is known to be very effective in treating patients with CML who have failed interferon-alpha, generating a complete hematological response rate of over 70%. In ongoing studies, we are now seeing promising preliminary results in CML patients who have developed resistance to Gleevec. I am pleased to be joining the ChemGenex Scientific Advisory Board to help further advance this program and to assist on other company programs," said Dr. Kantarjian.
Dr. Kantarjian has been associated with M.D. Anderson Cancer Center since 1981. He has served on the editorial boards of 10 scientific journals and has published more than 400 papers in scientific journals. Dr Kantarjian received his medical degree from the American University of Beirut and is board certified in internal medicine, medical oncology and hematology.
Greg Collier PhD, ChemGenex Pharmaceuticals chief executive officer says the appointment of Dr. Kantarjian reflects the company's move towards clinical development of internal and in-licensed lead therapeutics. "ChemGenex Pharmaceuticals currently has two compounds in Phase II clinical trial, Cephlatonin(R) and Quinamed(R) and the appointment of Dr Kantarjian strengthens our expertise in the oncology field. His contributions will be invaluable as we manage our significant portfolio of anti-cancer compounds, diabetes and obesity targets (partnered with Merck Sante) and depression and anxiety targets (partnered with Vernalis)."
About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)
ChemGenex Pharmaceuticals is a genomics-driven pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. The company was formed in 2004 from the merger of AGT Biosciences of Melbourne, Australia and privately held ChemGenex Therapeutics, Inc. of Menlo Park, California. The ChemGenex pipeline of novel small molecule, protein, and antibody therapeutics is based on internally discovered targets that play a role in important mechanisms underlying metabolic and CNS diseases, coupled with later-stage small molecules in clinical development for the treatment of cancer. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS".
Safe Harbor Statement
Certain statements made herein that use the words "estimate," 'project," "intend," "expect," "believe," and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company's technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company's technology, the market for the company's products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.
New! Sign up for local CML support group meetings in your local community at
http://cml.meetup.com
Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com
CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com
Post Message: [EMAIL PROTECTED]
Subscribe: [EMAIL PROTECTED]
Unsubscribe: [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED]
CML Group Web Site http://groups.yahoo.com/group/CML
| Yahoo! Groups Sponsor | |
|
|
Yahoo! Groups Links
- To visit your group on the web, go to:
http://groups.yahoo.com/group/CML/
- To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
- Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.
